Table II.
Blood cell count and biomarkers during treatment.
| Factor | EW02 (n=40) | Placebo (n=20) | P-value |
|---|---|---|---|
| C1D1 | |||
| WBC | 6200±1490 | 6360±1760 | 0.783 |
| ANC | 3860±1320 | 3700±1430 | 0.836 |
| IL-6 | 0.53±8.32 | 0.43±10.28 | 0.872 |
| G-CSF | 2.24±71.95 | 3.41±541.9 | 0.421 |
| C1D15 | |||
| WBC | 1860±520 | 1760±950 | 0.358 |
| ANC | 410±270 | 330±340 | 0.806 |
| IL-6 | 4.24±15.22 | 5.17±20.22 | 0.550 |
| G-CSF | 3.17±57.88 | 3.35±448.69 | 0.524 |
| C2D15 | |||
| WBC | 2140±620 | 2560±1100 | 0.424 |
| ANC | 694.2±386.8 | 706.3±665.5 | 0.932 |
| IL-6 | 2.60±6.00 | 2.88±5.76 | 0.521 |
| G-CSF | 2.39±58.23 | 3.12±370.2 | 0.541 |
WBC, white blood cell; ANC, absolute neutrophil count; IL-6, interleukin 6; G-CSF, granulocyte colony-stimulating factor.